



Here for you

### Pharmacy Services

## San Francisco Health Plan Pharmacy & Therapeutics Committee

Wednesday, July 17, 2024

7:30AM – 9:30AM

50 Beale St., 12<sup>th</sup> Floor, San Francisco, CA 94119

<b>Meeting called by:</b>	Steve O'Brien, MD	<b>Minutes:</b> Luke Nelson (SFHP Pharmacy Vendor Oversight Program Manager)
<b>Meeting Objective:</b>	Vote on proposed formulary and prior authorization (PA) criteria changes	<b>Type of meeting:</b> Quarterly
<b>Member Votes Cast:</b>	<p><b>Committee Chair:</b> Steve O'Brien, MD (SFHP Chief Medical Officer)</p> <p><b>Voting Members:</b> Nicholas Jew, MD Ronald Ruggiero, Pharm. D Robert (Brad) Williams, MD James Lee, MD Steven Wozniak, MD Maria Lopez, Pharm. D Linda Truong, Pharm. D Jamie Ruiz, MD</p>	<p><b>Others in Attendance:</b> Tammie Chau, Pharm. D (SFHP Clinical Pharmacist) Jessica Shost, Pharm. D (SFHP Clinical Pharmacist) Katrina Vo, Pharm. D (SFHP Clinical Pharmacist) Steve Nolan, Pharm. D (Prime Therapeutics Pharmacist) Sue Chan (SFHP Pharmacy Compliance Program Manager) Angela Zhao (SFHP Pharmacy Student Intern)</p> <p><b>Guests:</b> none</p>
<b>Members Absent:</b>	Joseph Pace, MD	
<b>Meeting Materials:</b>	<p>Summary of all approved changes is posted under "Materials" section at <a href="https://www.sfhp.org/about-us/committees/pharmacy-and-therapeutics-committee/">https://www.sfhp.org/about-us/committees/pharmacy-and-therapeutics-committee/</a></p> <p>SFHP formulary and prior authorization criteria are located at <a href="https://www.sfhp.org/providers/pharmacy-services/sfhp-formulary/">https://www.sfhp.org/providers/pharmacy-services/sfhp-formulary/</a></p>	

	Topic	Brought By	Discussion	Action
1.	Call to Order	Steve O'Brien, MD	<p>The meeting was called to order at 7:33 am.</p> <ul style="list-style-type: none"> <li>Attendance/Quorum</li> <li>Agenda overview</li> <li>Conflict of interest check</li> </ul>	Introduction and agenda topics done.
2.	Senior Medical Director informational Updates	Steve O'Brien, MD	<ul style="list-style-type: none"> <li>Dr. O'Brien introduction and background</li> <li>Medicare D-SNP and STARS updates</li> <li>New Pharmacy Director offer has been extended</li> </ul>	n/a

	Topic	Brought By	Discussion	Action
3.	Review and Approval of January 17, 2024, P&T minutes (pp.5 - 15 of July 2024 P&T Packet)	Steve O'Brien, MD	The committee approved the minutes as presented.	<b>VOTE:</b> <b><u>Review and Approval of April 17, 2024, P&amp;T Minutes</u></b> Approved minutes as presented.  <i>Vote: Unanimous approval (7/7)</i>
4.	<b>Adjourned to Closed Session</b>	Steve O'Brien, MD	Closed session began: 7:37 am.	
5.	<b><u>Drug Utilization Review (DUR) Reports</u></b> Prime/Magellan Retrospective DUR Quarterly Activities 1Q2024 (pp.17 – 23)	Jessica Shost, Pharm. D	<i>The plan presented a Magellan Rx rDUR Activities Report for 1Q2024 for committee review via Consent Calendar portion of committee packet.</i> <b>Summary:</b> Prime/Magellan reviews of the Healthy Workers HMO population have found a small number of members with concerning prescribing based on the topics of interest. This is consistent with the relatively small and engaged population of Healthy Workers HMO members (in comparison to Medi-Cal). Continued monitoring for different areas of rDUR interest will identify any concerning prescribing behavior or possible topics that require further intervention. <b>Materials:</b> <ul style="list-style-type: none"><li>• Statin letter</li><li>• Asthma letter</li><li>• Opioids letter</li></ul> <b><u>Committee Discussion:</u></b> <i>The committee had no comments or questions.</i>	<b>VOTE:</b> <b><u>Collective vote on Consent Calendar items 5 and 6.</u></b>  <b><u>Collective Consent Calendar Vote:</u></b> <b><u>Unanimous approval (8/8)</u></b>  <i>(Dr. Lopez arrived at 7:41am)</i>
6.	<b><u>Drug Utilization Review (DUR) Reports</u></b> Quarterly Prospective DUR Report 1Q2024 (pp.24 - 32)		<i>The plan presented a 1Q2024 DUR report on prospective edits for committee review via Consent Calendar portion of committee packet.</i> <b>Summary &amp; Recommendations</b> This report and analysis provide regular oversight for prospective DUR edits, including denial and report-only errors, and supports optimization of the formulary for safe and effective treatment while preventing waste and abuse. <b><u>Reporting Recommendations:</u></b> <ul style="list-style-type: none"><li>• Continue quarterly review of the Prospective DUR Report, with presentation of notable findings and resulting recommendations for formulary changes to P&amp;T as needed.</li></ul> <b><u>Drug-Specific Formulary Recommendations:</u></b> <ul style="list-style-type: none"><li>• None</li></ul> <b><u>DUR Education Recommendations:</u></b> <ul style="list-style-type: none"><li>• None</li></ul> <b><u>Committee Discussion:</u></b> <i>The committee had no comments or questions.</i>	

	Topic	Brought By	Discussion	Action
7.	<b>Cardiology</b> Antiplatelets Class Review (pp.34 - 48)	Katrina Vo, Pharm. D	<p>The plan presented a class review and recommendations for cardiology medications. Major recommendations included the following: <b>Last reviewed:</b> Oct 2021 <b>Formulary Update:</b> (Healthy Workers HMO and Healthy San Francisco):</p> <ul style="list-style-type: none"> <li>No changes recommended</li> </ul> <p><b>PA Criteria Update:</b></p> <ul style="list-style-type: none"> <li>None (no active criteria)</li> </ul> <p><b>DUR Update:</b></p> <ul style="list-style-type: none"> <li>None</li> </ul> <p><b>Committee Discussion:</b> Dr Truong asked regarding the difference in cost per Rx vs per month calculations. Dr. Vo clarified it is cost per claim vs cost per day supply per claim. Dr. Lopez commented on the decreased utilization of Brilinta. Dr. Vo noted updates to guidelines recommend shorter durations of dual antiplatelet therapies, which may be the cause behind the decrease in Brilinta utilization.</p>	<p><b>VOTE:</b> <b>Cardiology:</b> Approved recommendations as presented.</p> <p><b>Antiplatelets Class Review</b> <u>Vote: Unanimous approval (8/8)</u></p>
8.	<b>Cardiology</b> Dyslipidemia Class Review (pp.49 – 64)	Katrina Vo, Pharm. D	<p>The plan presented a class review and recommendations for cardiology medications. Major recommendations included the following: <b>Last reviewed:</b> Oct 2020 <b>Formulary Update:</b> (Healthy Workers HMO and Healthy San Francisco):</p> <ul style="list-style-type: none"> <li>Add choline fenofibrate (Trilipix®) to formulary T1 based on comparable cost-effectiveness and formulation</li> <li>benefits</li> </ul> <p><b>PA Criteria Update:</b></p> <ul style="list-style-type: none"> <li>None</li> </ul> <p><b>DUR Update:</b></p> <ul style="list-style-type: none"> <li>None</li> </ul> <p><b>Committee Discussion:</b> Dr O'Brien asked to clarify the PSK9's C1 tier label of Medi-Cal Rx CDL. Dr. Shost explained C1 is a Code 1 attestation requirement entered at point-of-sale by the pharmacy to ensure correct therapy usage.</p>	<p><b>VOTE:</b> <b>Cardiology:</b> Approved recommendations as presented.</p> <p><b>Dyslipidemia Class Review</b> <u>Vote: Unanimous approval (8/8)</u></p>
9.	<b>Endocrinology</b> Thyroid Disorder Class Review (pp.65 – 75)	Tammie Chau, Pharm. D	<p>The plan presented a class review and recommendations for endocrinology medications. Major recommendations included the following: <b>Last reviewed:</b> April 2021 <b>Formulary Update:</b> (Healthy Workers HMO and Healthy San Francisco):</p> <ul style="list-style-type: none"> <li>No changes recommended at this time</li> </ul> <p><b>PA Criteria Update:</b></p> <ul style="list-style-type: none"> <li>None (no active criteria)</li> </ul> <p><b>DUR Update:</b></p> <ul style="list-style-type: none"> <li>None</li> </ul> <p><b>Committee Discussion:</b></p>	<p><b>VOTE:</b> <b>Endocrinology:</b> Approved recommendations as presented.</p> <p><b>Thyroid Disorder Class Review</b> <u>Vote: Unanimous approval (8/8)</u></p>

	Topic	Brought By	Discussion	Action
			<p>The committee had no comments or questions.</p>	
10.	<p><b><u>Hematology</u></b> Iron Overload and Replacement Class Review (pp.76 – 88)</p>	Jessica Shost, Pharm. D	<p>The plan presented a class review and recommendations for hematology medications. Major recommendations included the following:  <b>Last reviewed:</b> July 2021  <b>Formulary Update:</b>            (Healthy Workers HMO and Healthy San Francisco):  <ul style="list-style-type: none"> <li>• No changes recommended</li> </ul> <b>PA Criteria Update:</b>  <ul style="list-style-type: none"> <li>• None</li> </ul> <b>DUR Update:</b>  <ul style="list-style-type: none"> <li>• None</li> </ul> <b>Committee Discussion:</b>  <i>Dr O'Brien asked to clarify OTC status, that only claims submitted via prescription at a pharmacy is covered, not OTC retail purchases. Dr. Shost confirmed that is correct, claims only paid thru a prescription at an in-network pharmacy.</i></p>	<p><b>VOTE:</b>  <b><u>Hematology:</u></b>            Approved recommendations as presented.</p> <p><b><u>Iron Overload and Replacement Class Review</u></b>  <i>Vote: Unanimous approval (8/8)</i></p>
11.	<p><b><u>Immunology</u></b> Immunosuppressants Class Review (pp.89 – 104)</p>	Katrina Vo, Pharm. D	<p>The plan presented a class review and recommendations for immunology medications. Major recommendations included the following:  <b>Last reviewed:</b> April 2021  <b>Formulary Update:</b>            (Healthy Workers HMO and Healthy San Francisco):  <ul style="list-style-type: none"> <li>• No changes recommended</li> </ul> <b>PA Criteria Update:</b>  <ul style="list-style-type: none"> <li>• Change Lupkynis® PA criteria name to Lupus and add Benlysta® criteria</li> </ul> <b>DUR Update:</b>  <ul style="list-style-type: none"> <li>• None</li> </ul> <b>Committee Discussion:</b>  <i>Dr. O'Brien asked about cost tables and if figures are what SFHP pays. Dr. Shost confirmed this is SFHP's cost minus rebate information as that is paid to the plan separately and not captured here. Medi-Cal Rx currently pays MAC pricing for our data, and dispensing fees paid are not captured.</i></p>	<p><b>VOTE:</b>  <b><u>Immunology:</u></b>            Approved recommendations as presented.</p> <p><b><u>Immunosuppressants Class Review</u></b>  <i>Vote: Unanimous approval (8/8)</i></p>

	Topic	Brought By	Discussion	Action
12.	<p><b><u>Pain</u></b> Muscle Relaxants Class Review (pp.105 – 112)</p>	Katrina Vo, Pharm. D	<p><i>The plan presented a class review and recommendations for pain medications. Major recommendations included the following:</i></p> <p><b>Last reviewed:</b> Oct 2021</p> <p><b>Formulary Update:</b> (Healthy Workers HMO and Healthy San Francisco):</p> <ul style="list-style-type: none"> <li>• No changes recommended</li> </ul> <p><b>PA Criteria Update:</b></p> <ul style="list-style-type: none"> <li>• None (no active criteria)</li> </ul> <p><b>DUR Update:</b></p> <ul style="list-style-type: none"> <li>• None</li> </ul> <p><b>Committee Discussion:</b> <i>Dr. O'Brien asked regarding the low cost and high abuse potential in this class, and what monitoring SFHP performs. Dr. Shost stated SFHP monitors opioid/relaxant combination therapies, opioid/benzo combination therapy, and general controlled substance reporting. If there are concerns SFHP will follow FWA processes for investigation. Current BEERS guidelines recommend against dual therapy due to addiction potential.</i></p>	<p><b>VOTE:</b> <b><u>Pain:</u></b> Approved recommendations as presented.</p> <p><b><u>Muscle Relaxants Class Review</u></b> <i>Vote: Unanimous approval (8/8)</i></p>
13.	<p><b><u>Rheumatology</u></b> Sohonos® (palovarotene) Monograph (pp.113 – 120)</p>	Jessica Shost, Pharm. D	<p><i>The plan presented a drug monograph and recommendations for a rheumatology medication. Major recommendations included the following:</i></p> <p><b>Last reviewed:</b> n/a</p> <p><b>Formulary Update:</b> (Healthy Workers HMO and Healthy San Francisco):</p> <ul style="list-style-type: none"> <li>• Maintain non-formulary status at this time due to lack of utilization and limited data available</li> </ul> <p><b>PA Criteria Update:</b></p> <ul style="list-style-type: none"> <li>• Leverage Non-Formulary Medications criteria for any requests</li> </ul> <p><b>DUR Update:</b></p> <ul style="list-style-type: none"> <li>• None</li> </ul> <p><b>Committee Discussion:</b> <i>Dr. Truong asked if this medication is a REMS drug. Dr. Shost stated it is not a REMS drug, likely due to the associated condition rarity. Dr. O'Brien asked if SFHP's standard Non-Formulary criteria was sufficient to address potential PA requests and specialist consultations vs specific criteria. Dr. Shost stated while a PCP could possibly request a PA for this product, that would not be best standard of practice due to condition complexity. Specialist referral would be a standard of care.</i></p>	<p><b>VOTE:</b> <b><u>Rheumatology:</u></b> Approved recommendations as presented.</p> <p><b><u>Sohonos® (palovarotene) Monograph</u></b> <i>Vote: Unanimous approval (8/8)</i></p>

	Topic	Brought By	Discussion	Action
14.	<p><b><u>Drug Utilization Review (DUR) Reports:</u></b>            Fraud, Waste and Abuse (FWA)            DUR: Controlled Substances Report 1Q2024            (pp.121 - 124)</p>	Jessica Shost, Pharm. D	<p><i>The plan presented a Fraud, Waste and Abuse (FWA) DUR analysis on Multiple Providers and Multiple Pharmacies for 1Q2024 for committee review via Consent Calendar portion of committee packet.</i></p> <p><b>Summary:</b>            Members utilizing multiple pharmacies or multiple providers were likely to be on ten or more unique medications. The members with a high pharmacy utilization appeared to be at risk of avoidable waste. Members with high provider and pharmacy usage likely have multiple primary care as well as specialty providers. High multiple provider utilization may also present a risk for duplicative therapy, supported by evidence of high number of unique medications.</p> <p><b>Recommendations:</b></p> <ul style="list-style-type: none"> <li>• Coordinate with CM to ensure that clients with multiple providers or multiple pharmacies receive a referral to ECM.</li> <li>• Continue to monitor with quarterly reports.</li> </ul> <p><b>Committee Discussion:</b>  <i>Dr. Ruggerio observed some provider counts being residents and students working with overseeing providers makes some numbers seem more dramatic than they seem. Dr. Lopez stated she has observed many poly-pharmacy users are using 90-day supplies from a specific location for maintenance meds that may not be where they “ad hoc” fill for convenience. Dr. O'Brien asked about Care Management referrals for these member cases and will follow up offline after and bring updates in the future. Dr. Shost clarified the top 50 value of the report was designed for scale vs trend drop offs, but improving trend views will be a takeaway for future reporting.</i></p>	Non-voting item
15.	<p><b><u>Drug Utilization Review (DUR) Reports:</u></b>            QI measures associated with DUR program            (no packet materials)</p>	Jessica Shost, Pharm. D	<p><i>The plan presented an update to DUR program quality improvement measures previously presented to committee.</i></p> <p><b>Committee Discussion:</b>  <i>The committee had no comments or questions.</i></p>	Non-voting item
16.	<p><b><u>Drug Utilization Review (DUR) Reports:</u></b>            Annual Medication Therapy Management Program Results 2023            (pp.125 - 131)</p>	Tammie Chau, Pharm. D	<p><i>The plan presented a MTM program update on 2023 year-end results for committee review.</i></p> <p><b>Summary:</b>            Pharmacists complete comprehensive medication assessments and medication reconciliation to ensure optimal drug, dose, and regimen for the members. All interventions and recommendations are documented in the Care Management system to promote transparency and integration of member's care. Medication Adherence Program was started in December 2022 as a quality improvement initiative for members who may not be eligible for Care Management program that could benefit from medication reconciliation.            The pharmacy benefit transitioned from SFHP to Medi-Cal Rx on January 1, 2022. This limited SFHP Pharmacy team's autonomy in coordination of medications such as medication synchronization, early</p>	Non-voting item

	Topic	Brought By	Discussion	Action
			<p>refill overrides, covering over-the-counter products, and authorizing non-formulary medications based on medical necessity. SFHP Pharmacy team ensured continuity of care for members by advocating at State level and participating in Magellan weekly office hour calls.</p> <p><b>Next Steps:</b> CMS has approved a MTM benefit for Medi-Cal beneficiaries; however, it is focused on community pharmacists providing face-to-face consultation. Advocacy for MTM benefit to include managed care pharmacists could increase the utility of this intervention, particularly for the high-risk population that are identified by Care Management and Quality Improvement program that require more support and care coordination.</p> <p><b>Committee Discussion:</b> <i>Dr. Lopez inquired if MTM activities were done by SFHP pharmacy staff or done by a contracted vendor. Dr. Chau clarified all MTM is done in-house, with Care Management (CM) handling the face-to-face portions of MTM. Dr. O'Brien stated that the MTM process and CM is being bolstered for the upcoming Medicare D-SNP line of business coming, and current caseload numbers of CM staff will be confirmed for committee in the future.</i></p>	
17.	<b>Reconvene in Open Session</b>	Steve O'Brien, MD	Open session resumed: 9:15 am.	<i>Non-voting item</i>
18.	Annual Pharmacy Policies and Procedures (P&Ps) Review (pp.132 - 152)	Sue Chan	<p><i>The plan presented changes to Pharmacy Policies and Procedures (P&amp;P) for P&amp;T committee annual review and approval:</i></p> <p><b>Document Changes</b> <u>Pharm-01 Pharmacy and Therapeutics Committee</u> <b>Update:</b></p> <ul style="list-style-type: none"> <li>• The policy is up for annual review. Made clarification to the number of SFHP voting seats.</li> <li>• Added language around regulatory-required coverage of FDA-approved OTC contraceptives.</li> <li>• Updated a law citation in procedure IV.F and the list of law references that are applicable since the last review.</li> </ul> <p><u>Pharm-07 Emergency Med Supply</u> <b>Update:</b></p> <ul style="list-style-type: none"> <li>• The policy is up for annual review. No changes were necessary.</li> </ul> <p><u>Pharm-11 Member Reimbursement for Pharmacy Services</u> <b>Update:</b></p> <ul style="list-style-type: none"> <li>• The policy is up for annual review. No changes were necessary.</li> </ul> <p><u>Pharm-16 Pharmacy Systems User Access</u> <b>Update:</b></p> <ul style="list-style-type: none"> <li>• The policy is up for annual review. No changes were necessary.</li> </ul> <p><b>Committee Discussion:</b> <i>The committee had no comments or questions.</i></p>	<p><b>VOTE:</b> <b><u>Review and Approval of Annual Pharmacy Policies and Procedures (P&amp;Ps)</u></b> Approved recommendations as presented.</p> <p><i><u>Vote: Unanimous approval (8/8)</u></i></p>

	Topic	Brought By	Discussion	Action
19.	Review and Approval of Interim Formulary Changes and Formulary Placement for New Drugs to Market (pp. 153 - 155)	Katrina Vo, Pharm. D	<i>The plan presented interim formulary changes and formulary status for new drugs to market.</i>  <b><u>Committee Discussion:</u></b> <i>The committee had no comments or questions.</i>	<b>VOTE:</b> <b><u>Review and Approval of Interim Formulary Changes and Formulary Placement for New Drugs to Market</u></b> Approve recommendations as presented.  <i>Vote: Unanimous approval (8/8)</i>
20.	Review and Approval of Prior Authorization Criteria Interim Changes (pp. 156 - 157)	Katrina Vo, Pharm. D	<i>The plan presented Prior Authorization Criteria interim changes (New Criteria, Revised Existing Criteria &amp; a table of criteria that were evaluated per the Annual review process where no clinical changes were made) for review and approval.</i>  <b><u>Committee Discussion:</u></b> <i>The committee had no comments or questions.</i>	<b>VOTE:</b> <b><u>Review and Approval of Prior Authorization Criteria Interim Changes</u></b> Approved recommendations as presented.  <i>Vote: Unanimous approval (8/8)</i>
21.	<b><u>Appendix</u></b> Prime/Magellan Drug Approvals Monthly Update: June 2024 and online Pipeline Report 1Q2024 (pp. 158 - 169)	Steve Nolan, Pharm. D	<i>The plan provided information published by Prime/Magellan Rx regarding new developments in the pharmacy market as of Q1 2024.</i>	Non-voting item
22.	Adjournment	Steve O'Brien, MD	The meeting adjourned at 9:31 am.  2024/25 P&T Committee Meeting dates are: <ul style="list-style-type: none"> <li>• Wednesday, October 16, 2024</li> <li>• Wednesday, January 15, 2025</li> <li>• Wednesday, April 16, 2025</li> <li>• Wednesday, July 16, 2025</li> </ul>	

Respectfully submitted by:

*Steve O'Brien MD*

-----  
Steve O'Brien, MD  
Pharmacy & Therapeutics Committee  
Chair

10/16/2024

-----  
Date